Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls.

Rögnvaldsson S, Steingrímsson V, Turesson I, Björkholm M, Landgren O, Kristinsson SY.

Haematologica. 2020 Feb 13. pii: haematol.2019.239632. doi: 10.3324/haematol.2019.239632. [Epub ahead of print] No abstract available.

2.

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K.

Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16443. [Epub ahead of print]

PMID:
32026474
3.

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Ossa JEA, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O.

Blood Cancer J. 2020 Jan 30;10(1):11. doi: 10.1038/s41408-020-0279-4.

4.

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Salcedo M, Lendvai N, Mastey D, Schlossman J, Hultcrantz M, Korde N, Mailankody S, Lesokhin A, Hassoun H, Smith E, Shah U, Diab V, Werner K, Landau H, Lahoud O, Drullinsky P, Shah G, Chung D, Scordo M, Giralt S, Landgren O.

Clin Lymphoma Myeloma Leuk. 2019 Dec 26. pii: S2152-2650(19)32235-9. doi: 10.1016/j.clml.2019.12.013. [Epub ahead of print] No abstract available.

PMID:
32001193
5.

Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors.

Hultcrantz M, Modlitba A, Vasan SK, Sjölander A, Rostgaard K, Landgren O, Hjalgrim H, Ullum H, Erikstrup C, Kristinsson SY, Edgren G.

Thromb Res. 2020 Feb;186:86-92. doi: 10.1016/j.thromres.2019.12.011. Epub 2019 Dec 20.

PMID:
31927271
6.

Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.

Maura F, Rustad EH, Yellapantula V, Łuksza M, Hoyos D, Maclachlan KH, Diamond BT, Greenbaum BD, Morgan G, Lesokhin A, Papaemmanuil E, Landgren O.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0689-0. [Epub ahead of print] No abstract available.

PMID:
31836853
7.

Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O.

JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4659. [Epub ahead of print]

PMID:
31830214
8.

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O.

Blood Cancer J. 2019 Dec 11;9(12):101. doi: 10.1038/s41408-019-0264-y. Erratum in: Blood Cancer J. 2020 Jan 30;10(1):11.

9.

Fractures and survival in multiple myeloma: results from a population-based study.

Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2019 Dec 2. pii: haematol.2019.230011. doi: 10.3324/haematol.2019.230011. [Epub ahead of print]

10.

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, Zhou K, Ro S, Mateos MV.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.

PMID:
31780415
11.

Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.

Kazandjian D, Landgren O.

Clin Adv Hematol Oncol. 2019 Oct;17(10):559-568.

PMID:
31730582
12.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD.

Sci Rep. 2019 Oct 16;9(1):14884. doi: 10.1038/s41598-019-51446-9.

13.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R.

J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049.

PMID:
31590151
14.

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O.

Am J Hematol. 2019 Dec;94(12):1364-1373. doi: 10.1002/ajh.25641. Epub 2019 Oct 21.

PMID:
31571261
15.

Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Bryant AR, Hilden P, Giralt S, Chung DJ, Maloy M, Landau H, Landgren O, Scordo M, Shah G, Smith EL, O'Reilly RJ, Perales MA, Koehne G.

Biol Blood Marrow Transplant. 2020 Jan;26(1):58-65. doi: 10.1016/j.bbmt.2019.08.023. Epub 2019 Sep 5.

PMID:
31493537
16.

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA.

Future Oncol. 2019 Oct;15(28):3267-3281. doi: 10.2217/fon-2019-0368. Epub 2019 Aug 9.

17.

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Clay-Gilmour AI, Rishi AR, Goldin LR, Greenberg-Worisek AJ, Achenbach SJ, Rabe KG, Maurer MJ, Kay NE, Shanafelt TD, Call TG, Brice Weinberg J, Camp NJ, Cerhan JR, Leis J, Norman A, Murray DL, Vincent Rajkumar S, Caporaso NE, Landgren O, McMaster ML, Slager SL, Vachon CM.

Blood Cancer J. 2019 Aug 5;9(8):59. doi: 10.1038/s41408-019-0220-x.

18.

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS.

Leukemia. 2019 Sep;33(9):2127-2143. doi: 10.1038/s41375-019-0517-6. Epub 2019 Jul 24. Review.

19.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
20.

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.

Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O, Lesokhin AM.

Blood Adv. 2019 Jul 9;3(13):2040-2044. doi: 10.1182/bloodadvances.2019032276.

21.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
22.

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.

Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O.

Am J Hematol. 2019 Jul;94(7):794-802. doi: 10.1002/ajh.25498. Epub 2019 May 13.

23.

Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Sverrisdóttir IS, Lund SH, Turesson I, Björkholm M, Goldin LR, Landgren O, Kristinsson SY.

Br J Haematol. 2019 Jul;186(1):37-44. doi: 10.1111/bjh.15883. Epub 2019 Mar 24.

PMID:
30906990
24.

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, Roshal M, Patel A, Chen D, Devlin SM, Jacobsen A, Huang Y, Miller JE, Papaemmanuil E, Landgren O.

PLoS One. 2019 Mar 22;14(3):e0211600. doi: 10.1371/journal.pone.0211600. eCollection 2019.

25.

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

Ye R, Kundrapu S, Gerson SL, Driscoll JJ, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e213-e220. doi: 10.1016/j.clml.2018.12.022. Epub 2019 Jan 3.

PMID:
30878316
26.

Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS).

Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer HP, Landgren O, Asmussen JT, Kaiser MF, Padhani A.

Radiology. 2019 Apr;291(1):5-13. doi: 10.1148/radiol.2019181949. Epub 2019 Feb 26.

PMID:
30806604
27.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Korde N, Mailankody S, Dew A, Papaemmanuil E, Maric I, Kwok M, Landgren O.

Blood Cancer J. 2019 Feb 4;9(2):15. doi: 10.1038/s41408-019-0177-9.

28.

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.

Arcila ME, Yu W, Syed M, Kim H, Maciag L, Yao J, Ho C, Petrova K, Moung C, Salazar P, Rijo I, Baldi T, Zehir A, Landgren O, Park J, Roshal M, Dogan A, Nafa K.

J Mol Diagn. 2019 Mar;21(2):330-342. doi: 10.1016/j.jmoldx.2018.10.008. Epub 2018 Dec 25.

29.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I.

Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6.

PMID:
30523328
30.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.

JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. No abstract available.

31.

Dietary intake is associated with risk of multiple myeloma and its precursor disease.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Steingrimsdottir L, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Torfadottir JE, Kristinsson SY.

PLoS One. 2018 Nov 1;13(11):e0206047. doi: 10.1371/journal.pone.0206047. eCollection 2018.

32.

Biological determinants of health disparities in multiple myeloma.

Smith CJ, Ambs S, Landgren O.

Blood Cancer J. 2018 Aug 28;8(9):85. doi: 10.1038/s41408-018-0118-z. Review.

33.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms.

Hultcrantz M, Björkholm M, Landgren O, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Aug 21;169(4):268. doi: 10.7326/L18-0245. No abstract available.

PMID:
30128518
34.

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients.

Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB.

Transplant Direct. 2018 May 15;4(6):e353. doi: 10.1097/TXD.0000000000000792. eCollection 2018 Jun.

35.

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.

Landgren O, Lu SX, Hultcrantz M.

Semin Hematol. 2018 Jan;55(1):44-50. doi: 10.1053/j.seminhematol.2018.03.001. Epub 2018 Mar 5. Review.

PMID:
29759154
36.

MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool.

Landgren O.

Semin Hematol. 2018 Jan;55(1):1-3. doi: 10.1053/j.seminhematol.2018.03.003. Epub 2018 Mar 15.

PMID:
29759146
37.

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O.

Bone Marrow Transplant. 2018 Nov;53(11):1445-1449. doi: 10.1038/s41409-018-0170-0. Epub 2018 May 4.

38.

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.

Landgren O, Zeig-Owens R, Giricz O, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl U, Pradhan K, Hall CB, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A, Prezant DJ.

JAMA Oncol. 2018 Jun 1;4(6):821-827. doi: 10.1001/jamaoncol.2018.0509.

39.

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O.

Eur J Haematol. 2018 Apr 20. doi: 10.1111/ejh.13083. [Epub ahead of print] Review.

40.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22. No abstract available.

41.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

42.

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.

Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, Dogan A, Roshal M.

Mod Pathol. 2018 Jun;31(6):881-889. doi: 10.1038/s41379-018-0011-0. Epub 2018 Feb 5.

43.

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML.

Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16.

PMID:
29335713
44.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O.

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. No abstract available.

45.

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Thorsteinsdottir S, Lund SH, Lindqvist EK, Thordardottir M, Sigurdsson G, Costello R, Burton D, Steingrimsdottir H, Gudnason V, Eiriksdottir G, Siggeirsdottir K, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Dec 21;1(27):2790-2798. doi: 10.1182/bloodadvances.2017010454. eCollection 2017 Dec 26.

46.

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, Jethava YS, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.

47.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

48.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

49.

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.

Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, Dogan A, Orfao A, Landgren O.

Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.

50.

Shall we treat smoldering multiple myeloma in the near future?

Landgren O.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204. doi: 10.1182/asheducation-2017.1.194. Review.

Supplemental Content

Loading ...
Support Center